Italia markets closed

Cyclacel Pharmaceuticals, Inc. (CYCC)

NasdaqCM - NasdaqCM Prezzo differito. Valuta in USD.
Aggiungi a watchlist
2,1099+0,1099 (+5,49%)
Alla chiusura: 04:00PM EDT
2,1250 +0,02 (+0,72%)
Dopo ore: 07:30PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente2,0000
Aperto2,0000
Denaro2,0900 x 800
Lettera2,5000 x 1400
Min-Max giorno2,0000 - 2,1398
Intervallo di 52 settimane1,8200 - 13,2000
Volume44.661
Media Volume156.670
Capitalizzazione2,781M
Beta (5 anni mensile)0,56
Rapporto PE (ttm)N/D
EPS (ttm)-26,7500
Prossima data utili09 mag 2024 - 13 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A16,00
  • GlobeNewswire

    Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

    - Key Catalysts ahead with Multiple Value Generating Readouts-- Expects to Release Phase 1/2 Data with Oral Fadraciclib -- Signals of Single-agent Efficacy with Oral Plogosertib -- Management to Host Conference Call at 4:30 pm EDT Today- BERKELEY HEIGHTS, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical leader in cell cycle checkpoint control developing innovative medicines based on cancer cell

  • GlobeNewswire

    Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results

    BERKELEY HEIGHTS, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2023 financial results on Wednesday August 9, 2023. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. Conference call information: Call: (800) 225-9448 / international call:

  • GlobeNewswire

    Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update

    - Key Catalysts ahead with multiple Value Generating Readouts -- Expects to Report Phase 1/2 Data Releases with Oral Fadraciclib -- Advancing single-agent Efficacy with Differentiated Oral Plogosertib -- Adds to Balance Sheet with non-dilutive $4.7 million from R&D Tax Credit -- Management to Host Conference Call at 4:30 pm EDT Today - BERKELEY HEIGHTS, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceu